134 related articles for article (PubMed ID: 36434836)
1. Association of Surgery and Chemotherapy in Stage IV Gastroenteropancreatic Neuroendocrine Carcinoma.
Wong WG; Dasari A; Shen C
J Surg Res; 2023 Mar; 283():407-415. PubMed ID: 36434836
[TBL] [Abstract][Full Text] [Related]
2. Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas.
Dasari A; Shen C; Devabhaktuni A; Nighot R; Sorbye H
Oncologist; 2022 Apr; 27(4):299-306. PubMed ID: 35380711
[TBL] [Abstract][Full Text] [Related]
3. Surgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States.
Kerekes D; Frey A; Bakkila B; Kunstman JW; Khan SA
J Surg Oncol; 2023 Oct; 128(5):790-802. PubMed ID: 37435780
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
5. The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.
Yoon SE; Kim JH; Lee SJ; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS; Kim ST
J Cancer; 2019; 10(14):3140-3144. PubMed ID: 31289584
[No Abstract] [Full Text] [Related]
6. Comparative Clinical Analysis of Gastroenteropancreatic Neuroendocrine Carcinomas with Liver Metastasis and Primary Hepatic Neuroendocrine Carcinomas.
Qiu MJ; Chen YB; Bi NR; Yang SL; He XX; Xiong ZF
Dis Markers; 2018; 2018():9191639. PubMed ID: 30416612
[TBL] [Abstract][Full Text] [Related]
7. Impact of Postoperative Chemotherapy on the Survival of Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinoma.
Schmitz R; Mao R; Moris D; Strickler JH; Blazer DG
Ann Surg Oncol; 2021 Jan; 28(1):114-120. PubMed ID: 32556871
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of small-cell versus large-cell gastroenteropancreatic neuroendocrine carcinomas: A population-based study.
Abdel-Rahman O; Fazio N
J Neuroendocrinol; 2021 May; 33(5):e12971. PubMed ID: 33870570
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review.
Ilett EE; Langer SW; Olsen IH; Federspiel B; Kjær A; Knigge U
Diagnostics (Basel); 2015 Apr; 5(2):119-76. PubMed ID: 26854147
[TBL] [Abstract][Full Text] [Related]
10. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
11. The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan.
Yamamoto S; Sakakibara N; Hirano H; Morizane C; Honma Y; Hijioka S; Okusaka T; Higashi T; Kawai A
Sci Rep; 2022 Oct; 12(1):17601. PubMed ID: 36266484
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
Hadoux J; Kanaan C; Durand A; Hescot S; Hautefeuille V; Cadiot G; Tauveron I; Laboureau S; Do Cao C; Walter T; Petorin C; Blanchet O; Jannin A; Gu C; Faron M; Leteurtre E; Rousselet MC; Zakeyh JJ; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Ducreux M; Scoazec JY; Baudin E
Eur J Cancer; 2021 Jul; 152():100-115. PubMed ID: 34090142
[TBL] [Abstract][Full Text] [Related]
13. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
[TBL] [Abstract][Full Text] [Related]
14. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.
Ali AS; Grönberg M; Federspiel B; Scoazec JY; Hjortland GO; Grønbæk H; Ladekarl M; Langer SW; Welin S; Vestermark LW; Arola J; Österlund P; Knigge U; Sorbye H; Grimelius L; Janson ET
PLoS One; 2017; 12(11):e0187667. PubMed ID: 29112960
[TBL] [Abstract][Full Text] [Related]
15. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
[TBL] [Abstract][Full Text] [Related]
16. The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.
Kim HK; Ha SY; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS; Kim ST
Oncotarget; 2017 Sep; 8(43):73974-73980. PubMed ID: 29088761
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
18. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.
Milione M; Maisonneuve P; Spada F; Pellegrinelli A; Spaggiari P; Albarello L; Pisa E; Barberis M; Vanoli A; Buzzoni R; Pusceddu S; Concas L; Sessa F; Solcia E; Capella C; Fazio N; La Rosa S
Neuroendocrinology; 2017; 104(1):85-93. PubMed ID: 26943788
[TBL] [Abstract][Full Text] [Related]
19. Impact of surgical approach on short- and long-term outcomes in gastroenteropancreatic neuroendocrine carcinomas.
Chen Q; Rhodin KE; Li K; Kanu E; Zani S; Lidsky ME; Zhao J; Wei Q; Luo S; Zhao H
HPB (Oxford); 2023 Oct; 25(10):1255-1267. PubMed ID: 37414710
[TBL] [Abstract][Full Text] [Related]
20. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
